Effects of Hemp-Derived Cannabinoids on Menopause Symptoms

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Menopause, Perimenopause

In brief

The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.

Key facts

Study ID

NCT07393672

Run by

Washington State University

People needed

104

Starts

2026-02-11

Expected to finish

2026-11-10

Last updated by the study team

2026-03-10

Who can join

Age: 40 and older, up to 60. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• designated female at birth
• 40-60 years of age
• able to give informed consent (no intellectual disability)
• stable pharmacotherapeutic regimen, no change in the past 3 months
• abstinent from regular cannabis use (<1x/month) for past year, and willing to abstain from use for 3 months
• abstinent for supplements, don't add any supplements (no changes in past 3 months)
• own a smartphone
• have access to Zoom on a secure, stable internet connection
• perimenopausal or menopausal

You may not qualify if…

• currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication
• severe depression, neurovegetative symptoms, or current suicidality
• psychosis or family history of psychosis
• pregnant or breastfeeding
• chemotherapy
• hypotension
• drug testing for work or other reasons
• illicit drug use in past 3 months (cannabis not illicit)
• heavy alcohol use (4 drinks more than 4x/week)
• international/air travel planned for more than one week in the next 3 months
• cocounut allergy

Where it is running

• Washington State University, Dept of Psychology — Pullman, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.